Arix Bioscience plc
("Company")
PDMR notifications & Director Shareholdings
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
The Company has been notified that Robert Lyne, Chief executive Officer, has sold a total of 107,657 Ordinary shares of 0.001 pence each in the Company ("Shares") on 04 May 2023 at an average price of 105 pence per share and bought on 04 May 2023, into his ISAs and SIPP, a total of 107,657 Shares at an average price of 107 pence per share.
The notification below, made in accordance with the requirements of UK Market Abuse Regulation, provides further detail on the respective transactions.
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| Robert Lyne | |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| Chief Executive Officer | |||
| b)
| Initial notification /Amendment
| Initial Notification | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a)
| Name
| Arix Bioscience plc | |||
| b)
| LEI
| 213800OVT3AHQCXNIX43
| |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a)
| Description of the financial instrument, type of instrument | Arix Bioscience plc Ordinary shares of 0.001 pence each | |||
| Identification code | GB00BD045071 | ||||
| b)
| Nature of the transaction
| Share Disposal | |||
| c) | Price(s) and volume(s) | | Price(s)£ | Volume(s) | |
| | | 1.) £1.052
2.) £1.053
3.) £1.0526
4.) £1.0425
| 22,238 20,000
57,000 | | |
| d)
| Aggregated information | | |||
| - Aggregated volume | 107,657 | ||||
| - Price (£) | £112,669.14 | ||||
| e)
| Date of the transaction
| 4 May 2023 | |||
| f)
| Place of the transaction
| London Stock Exchange | |||
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| Robert Lyne | |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| Chief Executive Officer | |||
| b)
| Initial notification /Amendment
| Initial Notification | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a)
| Name
| Arix Bioscience plc | |||
| b)
| LEI
| 213800OVT3AHQCXNIX43
| |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a)
| Description of the financial instrument, type of instrument | Arix Bioscience plc Ordinary shares of 0.001 pence each | |||
| Identification code | GB00BD045071 | ||||
| b)
| Nature of the transaction
| Share Purchase | |||
| c) | Price(s) and volume(s) | | Price(s)(£) | Volume(s) | |
| | | £1.069 £1.069 £1.068
| 57,014 8,419 42,224 | | |
| d)
| Aggregated information | | |||
| - Aggregated volume | 107,657 | ||||
| - Price (£) | £115,094.42 | ||||
| e)
| Date of the transaction
| 4 May 2023 | |||
| f)
| Place of the transaction
| London Stock Exchange | |||
Ends.
For further information please contact:
Kin Company Secretarial Limited, Company Secretary
+44 20 8819 6486
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.